TABLE 2.
Summary of TEAEs a
| Days 0‐69 | Steady state (days 70‐182) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Placebo | Lanadelumab | Placebo | Lanadelumab | |||||||
| 150 mg q4wks | 300 mg q4wks | 300 mg q2wks | Total | 150 mg q4wks | 300 mg q4wks | 300 mg q2wks | Total | |||
| N | 41 | 28 | 29 | 27 | 84 | 37 | 28 | 28 | 26 | 82 |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Any TEAE | 26 (63.4) | 21 (75.0) | 23 (79.3) | 25 (92.6) | 69 (82.1) | 24 (64.9) | 22 (78.6) | 18 (64.3) | 22 (84.6) | 62 (75.6) |
| Any related TEAE | 14 (34.1) | 14 (50.0) | 14 (48.3) | 17 (63.0) | 45 (53.6) | 7 (18.9) | 13 (46.4) | 10 (35.7) | 11 (42.3) | 34 (41.5) |
| Any serious TEAE | 0 | 0 | 2 (6.9) | 0 | 2 (2.4) | 0 | 0 | 1 (3.6) | 1 (3.8) | 2 (2.4) |
| Any related serious TEAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any related severe TEAE | 1 (2.4) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (1.2) |
| Hospitalization due to TEAEs | 0 | 0 | 2 (6.9) | 0 | 2 (2.4) | 0 | 0 | 1 (3.6) | 1 (3.8) | 2 (2.4) |
| Discontinuation due to TEAE | 1 (2.4) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (1.2) |
| Deaths due to TEAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
a
Excluding hereditary angioedema attack‐reported events.